{"id":11402311,"date":"2026-07-13T23:15:40","date_gmt":"2026-07-13T20:15:40","guid":{"rendered":"https:\/\/nostylelike.net\/product\/paclitaxel-actavis-300mg-vial\/"},"modified":"2026-08-27T14:19:11","modified_gmt":"2026-08-27T11:19:11","slug":"paclitaxel-actavis-300mg-vial","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/paclitaxel-actavis-300mg-vial\/","title":{"rendered":"Paclitaxel Actavis 6mg\/ml 300mg Vial | Chemotherapy Injection"},"content":{"rendered":"
\n

Quick Answer: What Is Paclitaxel?<\/h2>\n

Paclitaxel<\/strong> is a taxane-class chemotherapy medicine, derived originally from the Pacific yew tree, used in the treatment of ovarian, breast, and non-small-cell lung cancer, among other indications your oncologist will specify. This 300mg vial (6mg\/ml concentration) is administered exclusively as a hospital or infusion-center intravenous treatment by an oncology team \u2014 never self-administered, never taken at home. This page explains how it works and what to expect; your treatment plan, dosing, and schedule are set entirely by your oncologist based on your specific cancer, staging, and overall health.<\/p>\n<\/div>\n

Key Facts About Paclitaxel<\/h2>\n\n\n\n\n\n\n\n\n\n
Product Name<\/th>\nPaclitaxel Actavis 6mg\/ml, 300mg Vial<\/td>\n<\/tr>\n
Drug Class<\/th>\nTaxane chemotherapy (mitotic inhibitor)<\/td>\n<\/tr>\n
Common Uses<\/th>\nOvarian cancer, breast cancer, non-small-cell lung cancer, Kaposi’s sarcoma<\/td>\n<\/tr>\n
Administration<\/th>\nIntravenous infusion in a hospital\/oncology infusion center only<\/td>\n<\/tr>\n
Pre-Medication<\/th>\nStandard premedication protocol to prevent allergic reactions<\/td>\n<\/tr>\n
Monitoring<\/th>\nBlood counts before every cycle; continuous infusion monitoring<\/td>\n<\/tr>\n
Prescription Status<\/th>\nPrescription only \u2014 hospital\/oncology administration exclusively<\/td>\n<\/tr>\n
Price in Egypt<\/th>\n3,150 EGP per vial<\/td>\n<\/tr>\n<\/table>\n

\"paclitaxel<\/p>\n

How Paclitaxel Works<\/h2>\n

Paclitaxel disrupts the microtubule scaffolding that cancer cells need to divide. Unlike most chemotherapy agents that prevent microtubules from forming, paclitaxel does the opposite \u2014 it locks them in place, over-stabilizing them so the cell’s division machinery jams entirely. Cancer cells, which divide far more frequently than most healthy cells, are disproportionately caught in this jammed state and die; this selective vulnerability of rapidly dividing cells is the foundation of its anticancer effect, and also explains why fast-renewing normal tissues (bone marrow, hair follicles, gut lining) bear the brunt of its side effects.<\/p>\n

What Happens During Treatment<\/h2>\n